Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Protective effects of ginseng on neurological disorders.
Stable antigen-specific T-cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients.
Fulminant Central Plus Peripheral Nervous System Demyelination without Antibodies to Neurofascin.
Stem cell therapy for white matter disorders: don't forget the microenvironment!
Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel-group, randomized single-center study.
Role of Platelets in Neurodegenerative Diseases: A Universal Pathophysiology.
Natalizumab-induced autoimmune hepatitis in a patient with multiple sclerosis.
Combined treatment with minocycline and prednisone attenuates experimental autoimmune encephalomyelitis in C57 BL/6 mice.
[Symptoms of circadian desynchronization in patients with multiple sclerosis.]
[Neuromyelitis optica.]
Proteomic analysis of the anti-inflammatory action of minocycline.
Influence of treatments in multiple sclerosis disability: A cohort study.
Perceived impact of spasticity is associated with spatial and temporal parameters of gait in multiple sclerosis.
The influence of tetracyclines on T cell activation.
Aquaporins: important but elusive drug targets.
[Physical rehabilitation in multiple sclerosis: general principles and high-tech approaches].
Multiple sclerosis shrinks intralesional, and enlarges extralesional, brain parenchymal veins.
Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany.
Rebound after Fingolimod suspension in a pediatric-onset multiple sclerosis patient.
Patients' experiences of adapting to multiple sclerosis: a qualitative study.
Dynamics of saccade parameters in multiple sclerosis patients with fatigue.
Coping Strategies in Multiple Sclerosis Patients with Frontal Cognitive Disorders.
Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension.
Can we safely target the WNT pathway?
Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis.

Pages